Scilight Press

Author Information

Received: 26 Feb 2026 | Revised: 09 Apr 2026 | Accepted: 10 Apr 2026 | Published: 23 Apr 2026

Abstract

Keywords

Streptomyces | genome | antibiotic

References 

• 1.

  Conly, J.; Johnston, B. Where are all the new antibiotics? The new antibiotic paradox. Can. J. Infect. Dis. Med. Microbiol. 2005, 16, 159–160.

• 2.

  Hutchings, M.I.; Truman, A.W.; Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019, 51, 72–80.

• 3.

  Hibbing, M.E.; Fuqua, C.; Parsek, M.R.; et al. Bacterial competition: Surviving and thriving in the microbial jungle. Nat. Rev. Microbiol. 2010, 8, 15–25.

• 4.

  Cornforth, D.M.; Foster, K.R. Competition sensing: The social side of bacterial stress responses. Nat. Rev. Microbiol. 2013, 11, 285–293.

• 5.

  Shepherdson, E.M.; Baglio, C.R.; Elliot, M.A. Streptomyces behavior and competition in the natural environment. Curr. Opin. Microbiol. 2023, 71, 102257.

• 6.

  Watve, M.G.; Tickoo, R.; Jog, M.M.; et al. How many antibiotics are produced by the genus Streptomyces? Arch. Microbiol. 2001, 176, 386–390.

• 7.

  Bentley, S.D.; Chater, K.F.; Cerdeno-Tarraga, A.M.; et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 2002, 417, 141–147.

• 8.

  Ikeda, H.; Ishikawa, J.; Hanamoto, A.; et al. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nat. Biotechnol. 2003, 21, 526–531.

• 9.

  Wang, X.J.; Yan, Y.J.; Zhang, B.; et al. Genome sequence of the milbemycin-producing bacterium Streptomyces bingchenggensis. J. Bacteriol. 2010, 192, 4526–4527.

• 10.

  Augustijn, H.E.; van Nassauw, D.; Cernat, S.; et al. Regulatory genes as beacons for discovery and prioritization of biosynthetic gene clusters in Streptomyces. Biochemistry 2025, 64, 2877–2885.

• 11.

  Sensi, P.; Margalith, P.; Timbal, M.T. Rifomycin, a new antibiotic; preliminary report. Farm. Sci. 1959, 14, 146–147.

• 12.

  Sensi, P.; Greco, A.M.; Ballotta, R. Rifomycin. I. Isolation and properties of rifomycin B and rifomycin complex. Antibiot. Annu. 1959, 7, 262–270.

• 13.

  Bala, S.; Khanna, R.; Dadhwal, M.; et al. Reclassification of Amycolatopsis mediterranei DSM 46095 as Amycolatopsis rifamycinica sp. nov. Int. J. Syst. Evol. Microbiol. 2004, 54, 1145–1149.

• 14.

  Levine, D.P. Vancomycin: A history. Clin. Infect. Dis. 2006, 42, S5-12.

• 15.

  Jeong, H.; Sim, Y.M.; Kim, H.J.; et al. Genome sequence of the vancomycin-producing Amycolatopsis orientalis subsp. orientalis Strain KCTC 9412T. Genome Announc. 2013, 1, e00408-13.

• 16.

  Blazic, M.; Starcevic, A.; Lisfi, M.; et al. Annotation of the modular polyketide synthase and nonribosomal peptide synthetase gene clusters in the genome of Streptomyces tsukubaensis NRRL18488. Appl. Environ. Microbiol. 2012, 78, 8183–8190.

• 17.

  Ayuso-Sacido, A.; Genilloud, O. New PCR primers for the screening of NRPS and PKS-I systems in actinomycetes: Detection and distribution of these biosynthetic gene sequences in major taxonomic groups. Microb. Ecol. 2005, 49, 10–24.

• 18.

  Lin, Y.S.; Kieser, H.M.; Hopwood, D.A.; Chen, C.W. The chromosomal DNA of Streptomyces lividans 66 is linear. Mol. Microbiol. 1993, 10, 923–933.

• 19.

  Medema, M.H.; Trefzer, A.; Kovalchuk, A.; et al. The sequence of a 1.8-mb bacterial linear plasmid reveals a rich evolutionary reservoir of secondary metabolic pathways. Genome Biol. Evol. 2010, 2, 212–224.

• 20.

  Kinashi, H.; Shimaji, M.; Sakai, A. Giant linear plasmids in Streptomyces which code for antibiotic biosynthesis genes. Nature 1987, 328, 454–456.

• 21.

  Choulet, F.; Aigle, B.; Gallois, A.; et al. Evolution of the terminal regions of the Streptomyces linear chromosome. Mol. Biol. Evol. 2006, 23, 2361–2369.

• 22.

  Conte, J.E., Jr. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J. Infect. Dis. 1991, 163, 169–175.

• 23.

  Fischbach, M.A.; Walsh, C.T. Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: Logic, machinery, and mechanisms. Chem. Rev. 2006, 106, 3468–3496.

• 24.

  Scherlach, K.; Hertweck, C. Triggering cryptic natural product biosynthesis in microorganisms. Org. Biomol. Chem. 2009, 7, 1753–1760.

• 25.

  Rutledge, P.J.; Challis, G.L. Discovery of microbial natural products by activation of silent biosynthetic gene clusters. Nat. Rev. Microbiol. 2015, 13, 509–523.

• 26.

  Thaker, M.N.; Wang, W.; Spanogiannopoulos, P.; et al. Identifying producers of antibacterial compounds by screening for antibiotic resistance. Nat. Biotechnol. 2013, 31, 922–927.

• 27.

  Woo, P.C.; Lau, S.K.; Huang, Y.; et al. Genomic evidence for antibiotic resistance genes of actinomycetes as origins of antibiotic resistance genes in pathogenic bacteria simply because actinomycetes are more ancestral than pathogenic bacteria. Med. Hypotheses 2006, 67, 1297–1304.

• 28.

  Linares, J.F.; Gustafsson, I.; Baquero, F.; et al. Antibiotics as intermicrobial signaling agents instead of weapons. Proc. Natl. Acad. Sci. USA 2006, 103, 19484–19489.

• 29.

  Corzana, F.; Cuesta, I.; Freire, F.; et al. The pattern of distribution of amino groups modulates the structure and dynamics of natural aminoglycosides: Implications for RNA recognition. J. Am. Chem. Soc. 2007, 129, 2849–2865.

• 30.

  Carter, A.P.; Clemons, W.M.; Brodersen, D.E.; et al. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 2000, 407, 340–348.

• 31.

  Schatz, A.; Bugle, E.; Waksman, S.A. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 1944, 55, 66–69.

• 32.

  Flatt, P.M.; Mahmud, T. Biosynthesis of aminocyclitol-aminoglycoside antibiotics and related compounds. Nat. Prod. Rep. 2007, 24, 358–392.

• 33.

  Waksman, S.A.; Lechevalier, H.A. Neomycin, a new antibiotic active against streptomycin-resistant bacteria, including tuberculosis organisms. Science 1949, 109, 305–307.

• 34.

  Umezawa, H.; Ueda, M.; Maeda, K.; et al. Production and isolation of a new antibiotic: Kanamycin. J. Antibiot. 1957, 10, 181–188.

• 35.

  Stark, W.M.; Hoehn, M.M.; Knox, N.G. Nebramycin, a new broad-spectrum antibiotic complex. I. Detection and biosynthesis. Antimicrob. Agents Chemother. 1967, 7, 314–323.

• 36.

  Jenke-Kodama, H.; Dittmann, E. Evolution of metabolic diversity: Insights from microbial polyketide synthases. Phytochemistry 2009, 70, 1858–1866.

• 37.

  Mcguire, J.M.; Bunch, R.L.; Anderson, R.C.; et al. Ilotycin, a new antibiotic. Antibiot. Chemother. 1952, 2, 281–283.

• 38.

  Schlunzen, F.; Zarivach, R.; Harms, J.; et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 2001, 413, 814–821.

• 39.

  Campbell, E.A.; Korzheva, N.; Mustaev, A.; et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001, 104, 901–912.

• 40.

  August, P.R.; Tang, L.; Yoon, Y.J.; et al. Biosynthesis of the ansamycin antibiotic rifamycin: Deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699. Chem. Biol. 1998, 5, 69–79.

• 41.

  Hertweck, C.; Luzhetskyy, A.; Rebets, Y.; et al. Type II polyketide synthases: Gaining a deeper insight into enzymatic teamwork. Nat. Prod. Rep. 2007, 24, 162–190.

• 42.

  Zhang, Z.; Pan, H.X.; Tang, G.L. New insights into bacterial type II polyketide biosynthesis. F1000Research 2017, 6, 172.

• 43.

  McBride, C.M.; Miller, E.L.; Charkoudian, L.K. An updated catalogue of diverse type II polyketide synthase biosynthetic gene clusters captured from large-scale nucleotide databases. Microb. Genom. 2023, 9, mgen000965.

• 44.

  Duggar, B.M. Aureomycin; a product of the continuing search for new antibiotics. Ann. N. Y. Acad. Sci. 1948, 51, 177–181.

• 45.

  Zhang, W.; Ames, B.D.; Tsai, S.C.; et al. Engineered biosynthesis of a novel amidated polyketide, using the malonamyl-specific initiation module from the oxytetracycline polyketide synthase. Appl. Environ. Microbiol. 2006, 72, 2573–2580.

• 46.

  Finking, R.; Marahiel, M.A. Biosynthesis of nonribosomal peptides. Annu. Rev. Microbiol. 2004, 58, 453–488.

• 47.

  Marahiel, M.A. Working outside the protein-synthesis rules: Insights into non-ribosomal peptide synthesis. J. Pept. Sci. 2009, 15, 799–807.

• 48.

  Caboche, S.; Leclere, V.; Pupin, M.; et al. Diversity of monomers in nonribosomal peptides: Towards the prediction of origin and biological activity. J. Bacteriol. 2010, 192, 5143–5150.

• 49.

  Schwarzer, D.; Finking, R.; Marahiel, M.A. Nonribosomal peptides: From genes to products. Nat. Prod. Rep. 2003, 20, 275–287.

• 50.

  Walsh, C.T.; Chen, H.; Keating, T.A.; et al. Tailoring enzymes that modify nonribosomal peptides during and after chain elongation on NRPS assembly lines. Curr. Opin. Chem. Biol. 2001, 5, 525–534.

• 51.

  Walsh, C.T. Polyketide and nonribosomal peptide antibiotics: Modularity and versatility. Science 2004, 303, 1805–1810.

• 52.

  Brigham, R.B.; Pittenger, R.C. Streptomyces orientalis, n. sp., the source of vancomycin. Antibiot. Chemother. 1956, 6, 642–647.

• 53.

  Reynolds, P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 1989, 8, 943–950.

• 54.

  Marshall, C.G.; Broadhead, G.; Leskiw, B.K.; et al. D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc. Natl. Acad. Sci. USA 1997, 94, 6480–6483.

• 55.

  Tally, F.P.; DeBruin, M.F. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 2000, 46, 523–526.

• 56.

  Silverman, J.A.; Perlmutter, N.G.; Shapiro, H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 2003, 47, 2538–2544.

• 57.

  Doull, J.; Ahmed, Z.; Stuttard, C.; et al. Isolation and characterization of Streptomyces venezuelae mutants blocked in chloramphenicol biosynthesis. J. Gen. Microbiol. 1985, 131, 97–104.

• 58.

  He, J.; Magarvey, N.; Piraee, M.; et al. The gene cluster for chloramphenicol biosynthesis in Streptomyces venezuelae ISP5230 includes novel shikimate pathway homologues and a monomodular non-ribosomal peptide synthetase gene. Microbiology 2001, 147, 2817–2829.

• 59.

  Jones, A.; Vining, L.C. Biosynthesis of chloramphenicol in Streptomyces sp. 3022a. Identification of p-amino-L-phenylalanine as a product from the action of arylamine synthetase on chorismic acid. Can. J. Microbiol. 1976, 22, 237–244.

• 60.

  Fernandez-Martinez, L.T.; Borsetto, C.; Gomez-Escribano, J.P.; et al. New insights into chloramphenicol biosynthesis in Streptomyces venezuelae ATCC 10712. Antimicrob. Agents Chemother. 2014, 58, 7441–7450.

• 61.

  Podzelinska, K.; Latimer, R.; Bhattacharya, A.; et al. Chloramphenicol biosynthesis: The structure of CmlS, a flavin-dependent halogenase showing a covalent flavin-aspartate bond. J. Mol. Biol. 2010, 397, 316–331.

• 62.

  Hahn, F.E.; Wisseman, C.L., Jr.; Hopps, H.E. Mode of action of chloramphenicol, II. Inhibition of bacterial D-polypeptide formation by an L-stereoisomer of chloramphenicol. J. Bacteriol. 1954, 67, 674–679.

• 63.

  Tipper, D.J.; Strominger, J.L. Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl. Acad. Sci. USA 1965, 54, 1133–1141.

• 64.

  Kahan, J.S.; Kahan, F.M.; Goegelman, R.; et al. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot. 1979, 32, 1–12.

• 65.

  Reading, C.; Cole, M. Clavulanic acid: A beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 1977, 11, 852–857.

• 66.

  Tahlan, K.; Moore, M.A.; Jensen, S.E. Delta-(L-alpha-aminoadipyl)-L-cysteinyl-D-valine synthetase (ACVS): Discovery and perspectives. J. Ind. Microbiol. Biotechnol. 2017, 44, 517–524.

• 67.

  Luengo, J.M.; Lopez-Nieto, M.J.; Salto, F. Cyclization of phenylacetyl-L-cysteinyl-D-valine to benzylpenicillin using cell-free extracts of Streptomyces clavuligerus. J. Antibiot. 1986, 39, 1144–1147.

• 68.

  Dotzlaf, J.E.; Yeh, W.K. Copurification and characterization of deacetoxycephalosporin C synthetase/hydroxylase from Cephalosporium acremonium. J. Bacteriol. 1987, 169, 1611–1618.

• 69.

  Coque, J.J.; Perez-Llarena, F.J.; Enguita, F.J.; et al. Characterization of the cmcH genes of Nocardia lactamdurans and Streptomyces clavuligerus encoding a functional 3'-hydroxymethylcephem O-carbamoyltransferase for cephamycin biosynthesis. Gene 1995, 162, 21–27.

• 70.

  Williamson, J.M.; Inamine, E.; Wilson, K.E.; et al. Biosynthesis of the beta-lactam antibiotic, thienamycin, by Streptomyces cattleya. J. Biol. Chem. 1985, 260, 4637–4647.

• 71.

  Stapon, A.; Li, R.; Townsend, C.A. Synthesis of (3S,5R)-carbapenam-3-carboxylic acid and its role in carbapenem biosynthesis and the stereoinversion problem. J. Am. Chem. Soc. 2003, 125, 15746–15747.

• 72.

  Bodner, M.J.; Phelan, R.M.; Freeman, M.F.; et al. Non-heme iron oxygenases generate natural structural diversity in carbapenem antibiotics. J. Am. Chem. Soc. 2010, 132, 12–13.

• 73.

  Song, Y.; Zhang, X.; Zhang, Z.; et al. Physiology and transcriptional analysis of ppGpp-related regulatory effects in Streptomyces diastatochromogenes 1628. Microbiol. Spectr. 2023, 11, e01200–22.

• 74.

  Hesketh, A.; Sun, J.; Bibb, M. Induction of ppGpp synthesis in Streptomyces coelicolor A3(2) grown under conditions of nutritional sufficiency elicits actII-ORF4 transcription and actinorhodin biosynthesis. Mol. Microbiol. 2001, 39, 136–144.

• 75.

  Wietzorrek, A.; Bibb, M. A novel family of proteins that regulates antibiotic production in streptomycetes appears to contain an OmpR-like DNA-binding fold. Mol. Microbiol. 1997, 25, 1181.

• 76.

  Yan, Y.S.; Yang, Y.Q.; Zhou, L.S.; et al. MilR3, a unique SARP family pleiotropic regulator in Streptomyces bingchenggensis. Arch. Microbiol. 2022, 204, 631.

• 77.

  Rodriguez-Garcia, A.; Combes, P.; Perez-Redondo, R.; et al. Natural and synthetic tetracycline-inducible promoters for use in the antibiotic-producing bacteria Streptomyces. Nucleic Acids Res. 2005, 33, e87.

• 78.

  Zerikly, M.; Challis, G.L. Strategies for the discovery of new natural products by genome mining. ChemBioChem 2009, 10, 625–633.

• 79.

  Flardh, K.; Buttner, M.J. Streptomyces morphogenetics: Dissecting differentiation in a filamentous bacterium. Nat. Rev. Microbiol. 2009, 7, 36–49.

• 80.

  Huang, J.; Lih, C.J.; Pan, K.H.; et al. Global analysis of growth phase responsive gene expression and regulation of antibiotic biosynthetic pathways in Streptomyces coelicolor using DNA microarrays. Genes Dev. 2001, 15, 3183–3192.

• 81.

  Manteca, A.; Alvarez, R.; Salazar, N.; et al. Mycelium differentiation and antibiotic production in submerged cultures of Streptomyces coelicolor. Appl. Environ. Microbiol. 2008, 74, 3877–3886.

• 82.

  Zierhut, G.; Piepersberg, W.; Bock, A. Comparative analysis of the effect of aminoglycosides on bacterial protein synthesis in vitro. Eur. J. Biochem. 1979, 98, 577–583.

• 83.

  Busscher, G.F.; Rutjes, F.P.; van Delft, F.L. 2-Deoxystreptamine: Central scaffold of aminoglycoside antibiotics. Chem. Rev. 2005, 105, 775–791.

• 84.

  Hedley-Whyte, J.; Milamed, D.R. Tuberculous scrofula: Belfast experience. Ulst. Med. J. 2011, 80, 97–103.

• 85.

  Schatz, A.; Waksman, S.A. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc. Soc. Exp. Biol. Med. 1944, 57, 244–248.

• 86.

  Kingston, W. Streptomycin, Schatz v. Waksman, and the balance of credit for discovery. J. Hist. Med. Allied Sci. 2004, 59, 441–462.

• 87.

  Mingeot-Leclercq, M.P.; Glupczynski, Y.; Tulkens, P.M. Aminoglycosides: Activity and resistance. Antimicrob. Agents Chemother. 1999, 43, 727–737.

• 88.

  Distler, J.; Mansouri, K.; Mayer, G.; et al. Streptomycin biosynthesis and its regulation in Streptomycetes. Gene 1992, 115, 105–111.

• 89.

  Retzlaff, L.; Distler, J. The regulator of streptomycin gene expression, StrR, of Streptomyces griseus is a DNA binding activator protein with multiple recognition sites. Mol. Microbiol. 1995, 18, 151–162.

• 90.

  Huang, F.; Haydock, S.F.; Mironenko, T.; et al. The neomycin biosynthetic gene cluster of Streptomyces fradiae NCIMB 8233: Characterisation of an aminotransferase involved in the formation of 2-deoxystreptamine. Org. Biomol. Chem. 2005, 3, 1410–1418.

• 91.

  Llewellyn, N.M.; Spencer, J.B. Biosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics. Nat. Prod. Rep. 2006, 23, 864–874.

• 92.

  Fan, Q.; Huang, F.; Leadlay, P.F.; et al. The neomycin biosynthetic gene cluster of Streptomyces fradiae NCIMB 8233: Genetic and biochemical evidence for the roles of two glycosyltransferases and a deacetylase. Org. Biomol. Chem. 2008, 6, 3306–3314.

• 93.

  Caminero, J.A.; Sotgiu, G.; Zumla, A.; et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010, 10, 621–629.

• 94.

  Puius, Y.A.; Stievater, T.H.; Srikrishnan, T. Crystal structure, conformation, and absolute configuration of kanamycin A. Carbohydr. Res. 2006, 341, 2871–2875.

• 95.

  Yanai, K.; Murakami, T. The kanamycin biosynthetic gene cluster from Streptomyces kanamyceticus. J. Antibiot. 2004, 57, 351–354.

• 96.

  Park, J.W.; Park, S.R.; Nepal, K.K.; et al. Discovery of parallel pathways of kanamycin biosynthesis allows antibiotic manipulation. Nat. Chem. Biol. 2011, 7, 843–852.

• 97.

  Koch, K.F.; Rhoades, J.A. Structure of nebramycin factor 6, a new aminoglycosidic antibiotic. Antimicrob. Agents Chemother. 1970, 10, 309–313.

• 98.

  Kharel, M.K.; Basnet, D.B.; Lee, H.C.; et al. Isolation and characterization of the tobramycin biosynthetic gene cluster from Streptomyces tenebrarius. FEMS Microbiol. Lett. 2004, 230, 185–190.

• 99.

  Hirayama, T.; Tamegai, H.; Kudo, F.; et al. Biosynthesis of 2-deoxystreptamine-containing antibiotics in Streptoalloteichus hindustanus JCM 3268: Characterization of 2-deoxy-scyllo-inosose synthase. J. Antibiot. 2006, 59, 358–361.

• 100.

  Staunton, J.; Weissman, K.J. Polyketide biosynthesis: A millennium review. Nat. Prod. Rep. 2001, 18, 380–416.

• 101.

  Hopwood, D.A.; Sherman, D.H. Molecular genetics of polyketides and its comparison to fatty acid biosynthesis. Annu. Rev. Genet. 1990, 24, 37–66.

• 102.

  Donadio, S.; Staver, M.J.; McAlpine, J.B.; et al. Modular organization of genes required for complex polyketide biosynthesis. Science 1991, 252, 675–679.

• 103.

  Hutchinson, C.R. Microbial polyketide synthases: More and more prolific. Proc. Natl. Acad. Sci. USA 1999, 96, 3336–3338.

• 104.

  Yu, D.; Xu, F.; Zeng, J.; et al. Type III polyketide synthases in natural product biosynthesis. IUBMB Life 2012, 64, 285–295.

• 105.

  Katsuyama, Y.; Ohnishi, Y. Type III polyketide synthases in microorganisms. Methods Enzymol. 2012, 515, 359–377.

• 106.

  Dhakal, D.; Sohng, J.K.; Pandey, R.P. Engineering actinomycetes for biosynthesis of macrolactone polyketides. Microb. Cell Fact. 2019, 18, 137.

• 107.

  Haight, T.H.; Finland, M. Laboratory and clinical studies on erythromycin. N. Engl. J. Med. 1952, 247, 227–232.

• 108.

  Haight, T.H.; Finland, M. The antibacterial action of erythromycin. Proc. Soc. Exp. Biol. Med. 1952, 81, 175–183.

• 109.

  Shoemaker, E.H.; Yow, E.M. Erythromycin and related antibiotics: Applied pharmacology. Pediatr. Clin. North. Am. 1956, 3, 305–315.

• 110.

  Vester, B.; Douthwaite, S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob. Agents Chemother. 2001, 45, 1–12.

• 111.

  McDaniel, R.; Thamchaipenet, A.; Gustafsson, C.; et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc. Natl. Acad. Sci. USA 1999, 96, 1846–1851.

• 112.

  Caffrey, P.; Bevitt, D.J.; Staunton, J.; et al. Identification of DEBS 1, DEBS 2 and DEBS 3, the multienzyme polypeptides of the erythromycin-producing polyketide synthase from Saccharopolyspora erythraea. FEBS Lett. 1992, 304, 225–228.

• 113.

  Katz, L. The DEBS paradigm for type I modular polyketide synthases and beyond. Methods Enzymol. 2009, 459, 113–142.

• 114.

  Weber, J.M.; Leung, J.O.; Swanson, S.J.; et al. An erythromycin derivative produced by targeted gene disruption in Saccharopolyspora erythraea. Science 1991, 252, 114–117.

• 115.

  Summers, R.G.; Donadio, S.; Staver, M.J.; et al. Sequencing and mutagenesis of genes from the erythromycin biosynthetic gene cluster of Saccharopolyspora erythraea that are involved in L-mycarose and D-desosamine production. Microbiology 1997, 143, 3251–3262.

• 116.

  Zuckerman, J.M. Macrolides and ketolides: Azithromycin, clarithromycin, telithromycin. Infect. Dis. Clin. North. Am. 2004, 18, 621–649.

• 117.

  Finlay, A.C.; Hobby, G.L.; et al. Terramycin, a new antibiotic. Science 1950, 111, 85.

• 118.

  Chopra, I.; Roberts, M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 2001, 65, 232–260.

• 119.

  Pickens, L.B.; Tang, Y. Decoding and engineering tetracycline biosynthesis. Metab. Eng. 2009, 11, 69–75.

• 120.

  McMurry, L.M.; Park, B.H.; Burdett, V.; et al. Energy-dependent efflux mediated by class L (tetL) tetracycline resistance determinant from streptococci. Antimicrob. Agents Chemother. 1987, 31, 1648–1650.

• 121.

  Testa, R.T.; Petersen, P.J.; Jacobus, N.V.; et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob. Agents Chemother. 1993, 37, 2270–2277.

• 122.

  Brodersen, D.E.; Clemons, W.M., Jr.; Carter, A.P.; et al. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000, 103, 1143–1154.

• 123.

  Nigam, A.; Almabruk, K.H.; Saxena, A.; et al. Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant Mycobacterium tuberculosis. J. Biol. Chem. 2014, 289, 21142–21152.

• 124.

  Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 2013, 12, 371–387.

• 125.

  Sensi, P. History of the development of rifampin. Rev. Infect. Dis. 1983, 5, S402–S406.

• 126.

  Cohn, H.D. Clinical studies with a new rifamycin derivative. J. Clin. Pharmacol. J. New Drugs 1969, 9, 118–125.

• 127.

  Maggi, N.; Pasqualucci, C.R.; Ballotta, R.; et al. Rifampicin: A new orally active rifamycin. Chemotherapy 1966, 11, 285–292.

• 128.

  Grobbelaar, M.; Louw, G.E.; Sampson, S.L.; et al. Evolution of rifampicin treatment for tuberculosis. Infect. Genet. Evol. 2019, 74, 103937.

• 129.

  Britton, W.J.; Lockwood, D.N. Leprosy. Lancet 2004, 363, 1209–1219.

• 130.

  Griffith, D.E.; Brown-Elliott, B.A.; Wallace, R.J., Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: Results of a preliminary study. Clin. Infect. Dis. 2003, 37, 1178–1182.

• 131.

  Floss, H.G.; Yu, T.W. Rifamycin-mode of action, resistance, and biosynthesis. Chem. Rev. 2005, 105, 621–632.

• 132.

  Floss, H.G. Natural products derived from unusual variants of the shikimate pathway. Nat. Prod. Rep. 1997, 14, 433–452.

• 133.

  Kim, C.-G.; Kirschning, A.; Bergon, P.; et al. Biosynthesis of 3-amino-5-hydroxybenzoic acid, the precursor of mC7N units in ansamycin antibiotics. J. Am. Chem. Soc. 1996, 118, 7486–7491.

• 134.

  Kim, C.G.; Yu, T.W.; Fryhle, C.B.; et al. 3-amino-5-hydroxybenzoic acid synthase, the terminal enzyme in the formation of the precursor of mC7N units in rifamycin and related antibiotics. J. Biol. Chem. 1998, 273, 6030–6040.

• 135.

  Yu, T.W.; Muller, R.; Muller, M.; et al. Mutational analysis and reconstituted expression of the biosynthetic genes involved in the formation of 3-amino-5-hydroxybenzoic acid, the starter unit of rifamycin biosynthesis in Amycolatopsis mediterranei S699. J. Biol. Chem. 2001, 276, 12546–12555.

• 136.

  Griffith, R.S. Vancomycin use--an historical review. J. Antimicrob. Chemother. 1984, 14, 1–5.

• 137.

  de Lencastre, H.; Oliveira, D.; Tomasz, A. Antibiotic resistant Staphylococcus aureus: A paradigm of adaptive power. Curr. Opin. Microbiol. 2007, 10, 428–435.

• 138.

  Parenti, F.; Beretta, G.; Berti, M.; et al. Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties. J. Antibiot. 1978, 31, 276–283.

• 139.

  Barna, J.C.; Williams, D.H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 1984, 38, 339–357.

• 140.

  Leport, C.; Perronne, C.; Massip, P.; et al. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob. Agents Chemother. 1989, 33, 871–876.

• 141.

  Svetitsky, S.; Leibovici, L.; Paul, M. Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis. Antimicrob. Agents Chemother. 2009, 53, 4069–4079.

• 142.

  Hubbard, B.K.; Walsh, C.T. Vancomycin assembly: nature's way. Angew. Chem. Int. Ed. Engl. 2003, 42, 730–765.

• 143.

  Kahne, D.; Leimkuhler, C.; Lu, W.; et al. Glycopeptide and lipoglycopeptide antibiotics. Chem. Rev. 2005, 105, 425–448.

• 144.

  Pelzer, S.; Sussmuth, R.; Heckmann, D.; et al. Identification and analysis of the balhimycin biosynthetic gene cluster and its use for manipulating glycopeptide biosynthesis in Amycolatopsis mediterranei DSM5908. Antimicrob. Agents Chemother. 1999, 43, 1565–1573.

• 145.

  Sosio, M.; Kloosterman, H.; Bianchi, A.; et al. Organization of the teicoplanin gene cluster in Actinoplanes teichomyceticus. Microbiology 2004, 150, 95–102.

• 146.

  Phillips, I.; Edwards, J.R. Introduction: The modern gladiatorial arena: Gram-positive pathogens versus new therapies. Clin. Microbiol. Infect. 2005, 11, I.

• 147.

  Steenbergen, J.N.; Alder, J.; Thorne, G.M.; et al. Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 2005, 55, 283–288.

• 148.

  Buttress, J.A.; Schafer, A.B.; Koh, A.; et al. The last resort antibiotic daptomycin exhibits two independent antibacterial mechanisms of action. Nat. Commun. 2025, 16, 10320.

• 149.

  Miller, W.R.; Bayer, A.S.; Arias, C.A. Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci. Cold Spring Harb. Perspect. Med. 2016, 6, a026997.

• 150.

  Bionda, N.; Pitteloud, J.P.; Cudic, P. Cyclic lipodepsipeptides: A new class of antibacterial agents in the battle against resistant bacteria. Future Med. Chem. 2013, 5, 1311–1330.

• 151.

  Zakharova, A.A.; Efimova, S.S.; Ostroumova, O.S. State of the art of cyclic lipopeptide-membrane interactions: Pore formation and bilayer permeability. Pharmaceutics 2025, 17, 1142.

• 152.

  Miao, V.; Coeffet-LeGal, M.F.; Brian, P.; et al. Daptomycin biosynthesis in Streptomyces roseosporus: Cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 2005, 151, 1507–1523.

• 153.

  Baltz, R.H.; Miao, V.; Wrigley, S.K. Natural products to drugs: Daptomycin and related lipopeptide antibiotics. Nat. Prod. Rep. 2005, 22, 717–741.

• 154.

  Kopp, F.; Grunewald, J.; Mahlert, C.; et al. Chemoenzymatic design of acidic lipopeptide hybrids: New insights into the structure-activity relationship of daptomycin and A54145. Biochemistry 2006, 45, 10474–10481.

• 155.

  Nguyen, K.T.; Ritz, D.; Gu, J.Q.; et al. Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc. Natl. Acad. Sci. USA 2006, 103, 17462–17467.

• 156.

  Ehrlich, J.; Bartz, Q.R.; Smith, R.M.; et al. Chloromycetin, a new antibiotic from a soil actinomycete. Science 1947, 106, 417.

• 157.

  Rebstock, M.C.; Crooks, H.M.; Controulis, J.; et al. Chloramphenicol (Chloromycetin). 1 IV.1a Chemical Studies. J. Am. Chem. Soc. 1949, 71, 2458–2462.

• 158.

  Aronoff, D.M. Mildred Rebstock: Profile of the medicinal chemist who synthesized chloramphenicol. Antimicrob. Agents Chemother. 2019, 63, e00648-19.

• 159.

  Gaudelli, N.M.; Long, D.H.; Townsend, C.A. β-Lactam formation by a non-ribosomal peptide synthetase during antibiotic biosynthesis. Nature 2015, 520, 383–387.

• 160.

  Stapley, E.O.; Jackson, M.; Hernandez, S.; et al. Cephamycins, a new family of beta-lactam antibiotics. I. Production by actinomycetes, including Streptomyces lactamdurans sp. n. Antimicrob. Agents Chemother. 1972, 2, 122–131.

• 161.

  Nagarajan, R.; Boeck, L.D.; Gorman, M.; et al. Beta-lactam antibiotics from Streptomyces. J. Am. Chem. Soc. 1971, 93, 2308–2310.

• 162.

  Onishi, H.R.; Daoust, D.R.; Zimmerman, S.B.; et al. Cefoxitin, a semisynthetic cephamycin antibiotic: Resistance to beta-lactamase inactivation. Antimicrob. Agents Chemother. 1974, 5, 38–48.

• 163.

  Karady, S.; Pines, S.H.; Weinstock, L.M.; et al. Semisynthetic cephalosporins via a novel acyl exchange reaction. J. Am. Chem. Soc. 1972, 94, 1410–1411.

• 164.

  Rolinson, G.N. Evolution of beta-lactamase inhibitors. Rev. Infect. Dis. 1991, 13, S727–S732.

• 165.

  Fisher, J.; Charnas, R.L.; Knowles, J.R. Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry 1978, 17, 2180–2184.

• 166.

  Ball, A.P.; Geddes, A.M.; Davey, P.G.; et al. Clavulanic acid and amoxycillin: A clinical, bacteriological, and pharmacological study. Lancet 1980, 1, 620–623.

• 167.

  White, A.R.; Kaye, C.; Poupard, J.; et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: A review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 2004, 53, i3–i20.

• 168.

  Li, R.; Khaleeli, N.; Townsend, C.A. Expansion of the clavulanic acid gene cluster: Identification and in vivo functional analysis of three new genes required for biosynthesis of clavulanic acid by Streptomyces clavuligerus. J. Bacteriol. 2000, 182, 4087–4095.

• 169.

  Song, J.Y.; Jensen, S.E.; Lee, K.J. Clavulanic acid biosynthesis and genetic manipulation for its overproduction. Appl. Microbiol. Biotechnol. 2010, 88, 659–669.

• 170.

  Paradkar, A. Clavulanic acid production by Streptomyces clavuligerus: Biogenesis, regulation and strain improvement. J. Antibiot. 2013, 66, 411–420.

• 171.

  Gong, J.; Yi, J.S.; An, S.; et al. Integrated genomic-transcriptomic analysis of clavulanic acid production in differentially productive Streptomyces clavuligerus strains. Sci. Rep. 2025, 15, 45495.

• 172.

  Liras, P.; Gomez-Escribano, J.P.; Santamarta, I. Regulatory mechanisms controlling antibiotic production in Streptomyces clavuligerus. J. Ind. Microbiol. Biotechnol. 2008, 35, 667–676.

• 173.

  Salowe, S.P.; Marsh, E.N.; Townsend, C.A. Purification and characterization of clavaminate synthase from Streptomyces clavuligerus: An unusual oxidative enzyme in natural product biosynthesis. Biochemistry 1990, 29, 6499–6508.

• 174.

  Tally, F.P.; Jacobus, N.V.; Gorbach, S.L. In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob. Agents Chemother. 1980, 18, 642–644.

• 175.

  Kahan, F.M.; Kropp, H.; Sundelof, J.G.; et al. Thienamycin: Development of imipenen-cilastatin. J. Antimicrob. Chemother. 1983, 12, 1–35.

• 176.

  Zhanel, G.G.; Simor, A.E.; Vercaigne, L.; et al. Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can. J. Infect. Dis. 1998, 9, 215–228.

• 177.

  Kropp, H.; Sundelof, J.G.; Hajdu, R.; et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob. Agents Chemother. 1982, 22, 62–70.

• 178.

  Norrby, S.R.; Alestig, K.; Ferber, F.; et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob. Agents Chemother. 1983, 23, 293–299.

• 179.

  Nunez, L.E.; Mendez, C.; Brana, A.F.; et al. The biosynthetic gene cluster for the beta-lactam carbapenem thienamycin in Streptomyces cattleya. Chem. Biol. 2003, 10, 301–311.

• 180.

  Waksman, S.A.; Reilly, H.C.; Johnstone, D.B. Isolation of Streptomycin-producing Strains of Streptomyces griseus. J. Bacteriol. 1946, 52, 393–397.

• 181.

  Ball, S.; Bessell, C.J.; Mortimer, A. The production of polyenic antibiotics by soil streptomycetes. J. Gen. Microbiol. 1957, 17, 96–103.

• 182.

  Routien, J.B. Distribution of streptomycetes that produce antibiotics. J. Bacteriol. 1961, 81, 218–225.

• 183.

  Chan, E.; Martelli, P.; Hui, S.W.; et al. In vitro susceptibility of ceftolozane-tazobactam against Burkholderia pseudomallei. Antimicrob. Agents Chemother. 2018, 62, e00103-18.

• 184.

  Chan, E.; Wu, A.K.L.; Tse, C.W.S.; et al. In vitro susceptibility of Salmonella enterica serovar Typhi to ceftolozane/tazobactam. J. Antimicrob. Chemother. 2019, 74, 528–530.

• 185.

  Teng, J.L.L.; Chan, E.; Dai, A.C.H.; et al. In vitro susceptibility of typhoidal, nontyphoidal, and extended-spectrum-beta-lactamase-producing Salmonella to ceftolozane/tazobactam. Antimicrob. Agents Chemother. 2022, 66, e0122421.

• 186.

  Teng, J.L.L.; Chan, E.; Li, T.T.; et al. Antibiotic susceptibility of aerobic and facultative anaerobic Gram-negative rods in Hong Kong and implications on usefulness of ceftazidime-avibactam and ceftolozane-tazobactam. Antibiotics 2024, 13, 802.

• 187.

  Hannigan, G.D.; Prihoda, D.; Palicka, A.; et al. A deep learning genome-mining strategy for biosynthetic gene cluster prediction. Nucleic Acids Res. 2019, 47, e110.

• 188.

  Woo, P.C.Y. Rigorous analysis of microbes and infectious diseases using an expanding range of robust in silico technologies. eMicrobe 2025, 1, 1.

• 189.

  Frishman, D. From petri dishes to algorithms: The role of AI in modern microbiology. eMicrobe 2025, 1, 7.

• 190.

  Nahar, L. In silico technologies advancing microbial science: A visionary review. eMicrobe 2026, 2, 4.